The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia.
There is strong evidence that intravenous administration of ketamine following a standardized protocol could be used as a diagnostic test for a central sensitization in the central nervous system in patients with FM. The combination of a weak opioid and an NMDA-receptor antagonist with few side effects is presently a promise for treatment of pain in a subgroup of patients with FM. The response to intravenously administered ketamine may help select patients for this treatment modality.
Department of Rehabilitation Medicine, Faculty of Health Sciences, Linköping University, Pain Clinic, University Hospital, Linköping S-581 85, Sweden. karl-g@telia.com
Karl G
KG
Henriksson
Jan
J
Sörensen
D003915:Dextromethorphan / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D003915:Dextromethorphan